Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
PTGX Form 144 notice reporting a proposed sale of 1,750 shares of Common Stock tied to restricted stock vesting on 04/20/2026. The filing also lists recent dispositions by a holder: 46,203 shares on 01/27/2026 and 24,765 shares on 03/26/2026.
Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.
Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.
On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.
The Vanguard Group amended a Schedule 13G/A to report 0% beneficial ownership of Protagonist Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries now report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PTGX Form 144 shows recent proposed and completed sales of Common Stock. The excerpt lists a planned stock option exercise to sell 24,765 shares for cash on 03/26/2026. It also records two completed sales by Asif Ali: 46,203 shares on 01/27/2026 for $3,841,128.28 and 8,588 shares on 01/20/2026 for $708,327.08. Shares outstanding are listed as 63,808,716 as of 03/26/2026.
PTGX submitted a Form 144 reporting the sale of 15,000 shares via a stock option exercise to be settled for cash on 03/26/2026. The filing lists prior open-market dispositions by Arturo Molina, including 5,000 shares on 01/27/2026 and 13,151 shares on 01/23/2026.
Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock. On March 24–25, he exercised stock options covering 54,700 shares of Common Stock at an exercise price of $8.58 per share and acquired the same number of shares.
He then sold 54,700 Common Stock shares in open-market transactions at $101.00 per share. On March 23, he made a bona fide gift of 50,000 Common Stock shares to relatives. Following these transactions, Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock.
PTGX submitted a Form 144 reporting a proposed sale of 54,700 shares of Common Stock via an option exercise on 03/24/2026, with proceeds to be received in cash. The filing also lists prior open-market dispositions by Dinesh Patel of 19,315 shares on 01/23/2026, 24,890 shares on 01/26/2026, and 4,068 shares on 01/27/2026.